-+ 0.00%
-+ 0.00%
-+ 0.00%

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Barchart·08/05/2026 06:00:00
Listen to the news

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients

RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.